---
title: "Chugai Pharmaceutical Co (CHGCF) Receives a Buy from Citi"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284746521.md"
description: "Citi analyst maintained a Buy rating on Chugai Pharmaceutical Co today and set a price target of Yen13,500.00.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Chugai Pharmaceutical Co with a Yen10,399.70 average price target."
datetime: "2026-04-30T10:29:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284746521.md)
  - [en](https://longbridge.com/en/news/284746521.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284746521.md)
generator: "portal-rs"
---

# Chugai Pharmaceutical Co (CHGCF) Receives a Buy from Citi

Citi analyst maintained a Buy rating on Chugai Pharmaceutical Co today and set a price target of Yen13,500.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Chugai Pharmaceutical Co with a Yen10,399.70 average price target.

### Related Stocks

- [4519.JP](https://longbridge.com/en/quote/4519.JP.md)
- [1964.JP](https://longbridge.com/en/quote/1964.JP.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [CHGCY.US](https://longbridge.com/en/quote/CHGCY.US.md)
- [C-R.US](https://longbridge.com/en/quote/C-R.US.md)

## Related News & Research

- [Chugai files Japan approval bid for vamikibart in non-infectious uveitic macular edema](https://longbridge.com/en/news/296868472.md)
- [Chugai Pharmaceutical (TSE:4519) Stock Net Margin Strength Challenges Cost Pressure Concerns](https://longbridge.com/en/news/293850885.md)
- [Stocks in Play: Calian Group Ltd.](https://longbridge.com/en/news/297342889.md)
- [Chugai files Japan application for Tecentriq as adjuvant MSI-high colon cancer treatment](https://longbridge.com/en/news/295890880.md)
- [Chugai files Japan NDA for sparsentan in IgA nephropathy](https://longbridge.com/en/news/290271977.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**